Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XENE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.64B
- EPS (TTM)
- -$4.69
- Dividend yield
- None
- 52-week range
- 33.38 – 72.66
- Day range
- 36.81 – 37.97
- Volume / Avg
- 1.09M / 1.69M
- Beta
- —
- Shares outstanding
- 98.28M
52-week range
XENE stock today
Shares of Xenon Pharmaceuticals (XENE) finished lower on Nov 20 at $37.04, a drop of 1.38% or $0.52 per share, versus the S&P 500's 3.70% decline. At this level, XENE sits near the bottom of its 52-week range of $33.38 to $72.66: 49.0% below the high, set on Jul 9, 2026 and 11.0% above the low. XENE is down 17.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 10.0%.
Xenon Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$4.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Xenon Pharmaceuticals
Company profileXenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
- Headquarters
- Burnaby, BC
- Employees
- 358
- IPO year
- 2014
- Website
- xenon-pharma.com
Financial highlights
Full financialsIn fiscal 2025, Xenon Pharmaceuticals generated $7.5 million in revenue, up 0.0% from fiscal 2024. Xenon Pharmaceuticals reported a net loss of $345.9 million, compared with a loss of $234.3 million a year earlier. Operating margin was -4974.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $7.50M | $0 | $0 | $9.43M | $18.44M |
| Growth | — | — | -100.00% | -48.83% | -42.68% |
| Net income | $-345.91M | $-234.33M | $-182.39M | $-125.37M | $-78.88M |
| EPS (diluted) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
Analyst forecast
ForecastConsensus (18 analysts)
strong_buy
Avg. price target
$71.69+93.55%
- Strong buy 3
- Buy 14
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-1.15 vs $-1.14
- Surprise
- -0.88%
XENE news
All XENE news- Xenon Reports Q3 Results; Expects X-NOVA2 Data In December And Advances Pain Programs Toward Phase 2NasdaqXENE, BRK.A
- Xenon Pharmaceuticals Inc. Reports Q3 2026 Financial Results and Business UpdateNasdaqXENE, LEN.B
- Why is Xenon Pharmaceuticals stock sliding today?Investing.com
- Xenon Reports Q3 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Xenon to Present at Upcoming Investor ConferencesGlobeNewswire
- Xenon to Report Q3 2026 Financial Results on November 9, 2026GlobeNewswire
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?NasdaqXENE, JNJ, VNDA
Xenon Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TNGXTango Therapeutics Inc. | 21.73 | -4.32% | $3.68B | vs XENE |
| OGNOrganon & Co. | 13.89 | -0.14% | $3.65B | vs XENE |
| PBLSParabilis Medicines Inc. | 27.44 | -0.67% | $3.44B | vs XENE |
| ELVNEnliven Therapeutics Inc. | 46.53 | +0.26% | $3.42B | vs XENE |
| IRONDisc Medicine Inc. | 75.14 | -1.27% | $3.42B | vs XENE |
| VRDNViridian Therapeutics Inc. | 29.96 | -4.71% | $3.40B | vs XENE |
| AMLXAmylyx Pharmaceuticals Inc. | 26.02 | -0.69% | $3.35B | vs XENE |
| ARQTArcutis Biotherapeutics Inc. | 26.36 | -2.98% | $3.33B | vs XENE |
Indexes, lists and sector
Xenon Pharmaceuticals stock FAQ
What is Xenon Pharmaceuticals's stock price today?
XENE last traded at $37.04 as of Nov 20, 4:00 PM EST, down 1.38% on the day. Prices are delayed at least 15 minutes.
Who is Xenon Pharmaceuticals's CEO?
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. is the chief executive officer of Xenon Pharmaceuticals Inc., which has about 358 employees.
What is the XENE 52-week high?
The 52-week high for XENE is $72.66 and the 52-week low is $33.38. The stock is currently 49.0% below its high.